Provectus (NASDAQ: PVCT) CEO converts 8% note into Series D-1 equity

Rhea-AI Filing Summary

Provectus Biopharmaceuticals CEO Edward Pershing reported a non-cash conversion of debt into equity. An 8% unsecured convertible promissory note automatically converted into 30,202 shares of Series D-1 Convertible Preferred Stock on April 29, 2026 at a conversion price of $2.862 per share.

Each Series D-1 preferred share is convertible into 10 shares of common stock, so the new preferred position represents 302,020 common shares. After this derivative exercise/conversion, Pershing directly owns 2,774,233 shares of Provectus common stock, with no remaining derivative position shown in this filing.

Insider Trade Summary

30,202 shares exercised/converted

Mixed 2 txns

Insider Pershing Edward

Role CEO

Type	Security	Shares	Price	Value
Exercise	8% Unsecured Convertible Promissory Note	0	$0.00	--
Exercise	Series D-1 Convertible Preferred Stock	30,202	$0.00	--

Holdings After Transaction: 8% Unsecured Convertible Promissory Note — 0 shares (Direct, null); Series D-1 Convertible Preferred Stock — 2,774,233 shares (Direct, null)

Footnotes (1)

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing. On April 29, 2026, the 2025 Note was converted into 30,202 shares of Series D-1 Preferred Stock.

Key Figures

Series D-1 shares received: 30,202 shares Conversion price of note: $2.862 per share Common shares underlying D-1: 302,020 shares +2 more

5 metrics

Series D-1 shares received 30,202 shares Converted from 8% unsecured convertible promissory note on April 29, 2026

Conversion price of note $2.862 per share Price per share for conversion into Series D-1 Preferred Stock

Common shares underlying D-1 302,020 shares Each Series D-1 share converts into 10 common shares

Common shares after transaction 2,774,233 shares Total Provectus common stock held directly by CEO after conversion

Interest rate on note 8% Unsecured convertible promissory note converted into Series D-1 Preferred Stock

Key Terms

Series D-1 Convertible Preferred Stock, 8% Unsecured Convertible Promissory Note, conversion price, automatic conversion

4 terms

Series D-1 Convertible Preferred Stock financial

"Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock"

8% Unsecured Convertible Promissory Note financial

"The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note"

conversion price financial

"convert ... into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862"

The conversion price is the fixed price at which a convertible security, like a bond or preferred stock, can be exchanged for shares of common stock. It acts like a set rate that determines how many shares an investor can receive if they choose to convert their investment. This helps investors understand the value and potential benefits of converting their securities into company shares.

automatic conversion financial

"The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pershing Edward

(Last) (First) (Middle)

800 S. GAY STREET,

SUITE 1610

(Street)

KNOXVILLE TENNESSEE 37929

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROVECTUS BIOPHARMACEUTICALS, INC. [ PVCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
8% Unsecured Convertible Promissory Note	$2.862	04/29/2026		M			$80,000	04/29/2025	04/29/2026	Series D-1 Convertible Preferred Stock(3)(4)	30,202	$0	$1,065,000	D
Series D-1 Convertible Preferred Stock	(1)	04/29/2026		M		30,202		04/29/2026	(2)	Common Stock	302,020	$0	2,774,233	D

Explanation of Responses:

1. Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock").

2. The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

3. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing.

4. On April 29, 2026, the 2025 Note was converted into 30,202 shares of Series D-1 Preferred Stock.

	/s/ Edward Pershing	04/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did PVCT CEO Edward Pershing report in this Form 4 filing?

Edward Pershing reported a conversion of debt into equity. An 8% unsecured convertible promissory note automatically converted into 30,202 shares of Series D-1 preferred stock, which are convertible into 302,020 common shares of Provectus Biopharmaceuticals.

How many Provectus (PVCT) shares does the CEO hold after this transaction?

Following the conversion, Edward Pershing directly holds 2,774,233 shares of Provectus common stock. This reflects the addition of shares underlying 30,202 Series D-1 preferred shares, each of which is convertible into 10 common shares under the stated terms.

What are the terms of the 8% unsecured convertible promissory note in the PVCT filing?

The 8% unsecured convertible promissory note could convert into Series D-1 preferred shares at $2.862 per share. If not converted earlier, the note automatically converted into 30,202 Series D-1 preferred shares twelve months after its issue date, which occurred on April 29, 2026.

How does the Series D-1 Convertible Preferred Stock convert into PVCT common shares?

Each share of Series D-1 Convertible Preferred Stock converts into 10 shares of Provectus common stock. It will automatically convert into common stock on December 31, 2028, unless converted earlier in line with the Certificate of Designation terms governing this preferred series.

Was there an open-market buy or sell of PVCT shares in this Form 4?

No open-market buy or sell occurred in this Form 4. The filing reports derivative exercises/conversions only, turning an 8% unsecured convertible promissory note into Series D-1 preferred stock and thereby increasing the CEO’s equity exposure without a market purchase or sale.